Press Releases

RSS
  • Dec 15, 2016
    ENGLEWOOD, Colo., Dec. 15, 2016 /PRNewswire/ -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced that it has entered into agreements with five leading Asian specialty medical distributors to commercialize the Company's MiOXSYS® System. MiOXSYS is the company's in vitro diagnostic...
    Dec 5, 2016
    Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view presentation...
    Dec 1, 2016
    ENGLEWOOD, Colo., Dec. 1, 2016 /PRNewswire/ -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced that Josh Disbrow, Chairman & Chief Executive Officer, and Jarrett Disbrow, Chief Operating Officer, will present a corporate overview at the 9th Annual LD Micro Investor Conference ...
    Nov 30, 2016
    ENGLEWOOD, Colo., Nov. 30, 2016 /PRNewswire/ -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced the summary of findings that demonstrated significant clinical improvements in erectile function and mood in hypogonadal men treated with Natesto® nasal testosterone gel (NTG).  Nates...
    Nov 28, 2016
    ENGLEWOOD, Colo., Nov. 28, 2016 /PRNewswire/ -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced that Chief Executive Officer Josh Disbrow will present live at VirtualInvestorConferences.com on December 1, 2016....
    Nov 17, 2016
    ENGLEWOOD, Colo., Nov. 17, 2016 /PRNewswire/ -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced that clinical data demonstrating the reproducibility and reliability of its novel infertility diagnosis platform MiOXSYS™ has been published in the peer-reviewed, scientific journal R...
    Nov 7, 2016
    ENGLEWOOD, Colo., Nov. 7, 2016 /PRNewswire/ -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, provided today an overview of its business and growth strategy, as well as its financial results for the quarter ended September 30, 2016.  The Company will host a live conference call and webcast toda...
    Nov 3, 2016
    ENGLEWOOD, Colo., Nov. 3, 2016 /PRNewswire/ -- Aytu BioScience Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, announced today that the company will present its operational results for the first quarter of fiscal 2017 on Monday, November 7, 2016, at 4:30 p.m. ET.  The company will review recent accomplishments a...
    Nov 2, 2016
    ENGLEWOOD, Colo., Nov. 2, 2016 /PRNewswire/ -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced the closing of its previously announced underwritten public offering of 5,735,000 shares of its common stock and warrants to purchase up to an aggregate of 6,020,245 shares of its commo...
    Nov 1, 2016
    ENGLEWOOD, Colo., Nov. 1, 2016 /PRNewswire/ -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced that it presented five posters demonstrating the clinical potential of MiOXSYS™, Aytu's rapid in vitro diagnostic system for the qualitative measurement of static oxidation-reduction...